Inside Paradromics, the Neuralink competitor hoping to commercialize brain implants before the end of the decade

The following is a transcript of the video.

Matt Angle: The brain is a super fascinating organ. We have about 85 billion neurons and every neuron is a million times slower than a computer chip. And yet, the brain does incredible things.

But what that means is that if you want to get data in and out of the brain, you have to be able to talk to a ton of different neurons simultaneously. And that's where the emphasis on building these high-speed, high-data-rate devices came from.

My name is Matt Angle and I'm the CEO and founder of Paradromics.

Paradromics' mission is to transform otherwise untreatable health conditions in brain health into solvable technology problems. We're fundamentally building a medical device to serve unmet needs.

What that does is it allows us to connect to the brain and receive data from the brain. Those medical devices are prescribed by physicians. They're implanted in patients. And they're paid for by private insurance companies.

I think a reasonable expectation for these kinds of devices would be around $100,000 per device.

The first patients to benefit from Paradromics technology will be patients who have lost the ability to communicate due to paralysis — people with ALS, spinal cord injury, who are trying to get back to normal communication with their families.

But the same kind of device can also read out things like whether someone is depressed, or whether someone's experiencing chronic pain. And so where we see the real clinical impact of BCI [brain computer interfaces] is that it's going to become a first line for many people with neurological health conditions.

Vikash Gilja: My name is Vikash Gilja. I'm the chief scientific officer at Paradromics. The reason we've chosen to focus on motor and